Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00914927 · ClinicalTrials.gov registry record · Phase 2
Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures
A Phase 2 study of Thrombocytopenia Related to Chronic Liver Disease, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 1
- Study location
NCT00914927: Completed Phase 2 study of Thrombocytopenia Related to Chronic Liver Disease, sponsored by Eisai.
NCT00914927 is a Phase 2 study of Thrombocytopenia Related to Chronic Liver Disease that has completed, run by Eisai. The registered enrollment target is 130 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00914927, a Phase 2 study of Thrombocytopenia Related to Chronic Liver Disease, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the efficacy of once-daily Oral avatrombopagin subjects with chronic liver diseases and thrombocytopenia prior to elective surgical or diagnostic procedures, to evaluate the safety of short-term administration of avatrombopag and to evaluate the pharmacokinetics (PK) of E5501.
Primary Outcome
Platelet counts (PC) were determined from blood draws. A responder is defined as a participant having an increase of at least 20,000/mm\^3 PC from Baseline and a PC greater than 50,000/mm\^3 at least once during Day 4 through Day 8. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (end of treatment (EOT)), the postdose windows applied. If there was more than one PC within the
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Avatrombopag
Study Locations (1)
Louisiana
- Ochsner Clinic Foundation - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-12-21 |
| Phase | Phase 2 |
What the finished NCT00914927 record still lists
NCT00914927 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Thrombocytopenia Related to Chronic Liver Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00914927 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT00914927 about?
NCT00914927 is a clinical study titled "Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures". The purpose of this study is to evaluate the efficacy of once-daily Oral avatrombopagin subjects with chronic liver diseases and thrombocytopenia prior to elective surgical or diagnostic procedures, to evaluate the safety of short-term administration of avatrombopag and to evaluate the pharmacokinet...
What is the current status of trial NCT00914927?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2009-05. Estimated completion is 2011-12-21.
What conditions does trial NCT00914927 study?
This clinical trial studies the following conditions: Thrombocytopenia Related to Chronic Liver Disease.
What interventions are being tested in trial NCT00914927?
The interventions under investigation include: Placebo (DRUG), Avatrombopag (DRUG).
Who is sponsoring clinical trial NCT00914927?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00914927 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00914927's enrollment target sits among peer trials
130 543rd of 2000 higher than 1,448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia